BridgeBio Pharma Is Maintained at Outperform by Leerink Partners

Dow JonesOct 17 22:53 · Ratings

Leerink Partners Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Cuts Target Price to $46

Futu NewsOct 17 20:31 · Ratings

J.P. Morgan Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Announces Target Price $43

Futu NewsOct 17 19:31 · Ratings

BridgeBio Pharma Receives 'Buy' Rating Amid Positive Regulatory Outlook for Acoramidis

TipRanksOct 16 20:47 · Ratings

Scotiabank Initiates BridgeBio Pharma at Sector Outperform With $44 Price Target

MT NewswiresOct 16 20:23 · Ratings

Express News | BridgeBio Pharma Inc : Leerink Partners Cuts Target Price to $47 From $48

BreakingsOct 14 18:14